Filing identity and reporting period
Important: The supplied filing is Rexahn Pharmaceuticals, Inc.’s Form 10-Q for the quarter ended June 30, 2019—not an Opus Genetics, Inc. filing. The company described itself as a clinical-stage oncology biopharmaceutical business with no product sales. This summary reflects the supplied Rexahn filing.
Financial results and liquidity
- Revenue: $0 for the three and six months ended June 30, 2019 and the comparable 2018 periods. No profit or meaningful operating margin was reported.
- Net loss: Q2 2019 loss was $2.46 million, or $0.61 per share, versus $3.84 million, or $1.45 per share, in Q2 2018. First-half loss was $4.81 million, or $1.23 per share, versus $5.91 million, or $2.24 per share, in first-half 2018.
- Expenses: Q2 general and administrative expense was $1.34 million (down 14.6%) and research and development expense was $1.65 million (down 52.0%). First-half amounts were $3.04 million (down 10.6%) and $3.89 million (down 48.1%), respectively. R&D reductions primarily reflected lower drug-manufacturing costs, restructuring, and completed or paused trial enrollment.
- Cash flow: Operating cash use was $6.19 million in the first half, compared with $10.05 million in 2018. Investing activities used $2.90 million; financing provided $7.65 million, mainly from the January offering. Cash and cash equivalents declined by $1.43 million to $7.31 million.
- Liquidity: Marketable securities were $8.95 million, making cash, cash equivalents and securities approximately $16.26 million. Current assets were $17.29 million versus current liabilities of $3.55 million. Management said available funds were expected to cover current activities for at least 12 months after issuance of the statements, while also noting that additional capital would be needed to continue development.
- Debt and other liabilities: The balance sheet reports no conventional debt. Total liabilities were $4.05 million, including $366,732 of warrant liabilities and $266,662 of operating lease liabilities. The company recorded a $1.94 million first-half noncash gain from revaluing liability-classified warrants; this materially reduced reported net loss.
Material changes and business developments
- In January 2019, Rexahn raised approximately $8.6 million gross through an offering of 895,834 common shares and warrants; net proceeds were approximately $7.65 million. The warrants were immediately exercisable at $9.60 per share. A 1-for-12 reverse stock split took effect in April; reported share figures were retroactively adjusted.
- A February collaboration with BioSense Global covers RX-3117 development and commercialization in specified Asian markets. The $3.0 million upfront payment included $1.5 million received by June 30, with the balance due August 24, 2019. No revenue was recognized by quarter-end because the license and clinical-material performance obligations had not yet been satisfied; the received amount was recorded as deferred revenue. Potential milestone payments total up to $226 million, plus tiered royalties, but are contingent and not assured.
- RX-3117’s Phase 2a combination study with Abraxane reached target enrollment in February 2019. The filing cites preliminary, unaudited data through July 24: a 23% overall response rate among 40 patients with at least one on-treatment scan and median progression-free survival of approximately 5.4 months. Complete data was expected in 2020.
- Enrollment in the RX-5902 TNBC monotherapy study had stopped; the company was evaluating whether to proceed with a proposed combination study with Merck’s KEYTRUDA. RX-0301 remained in preclinical development with Haichang; an IND filing was expected in 2020. The internally funded RX-0201 program had been discontinued.
- The company terminated its laboratory lease in February and sold its lab equipment. It amended its office lease, with an optional termination date in June 2021 that management considered likely to use.
Outlook, risks and contingencies
Management anticipated continued losses in 2019 and beyond and said future spending would depend on available funding, project selection and clinical progress. It could not estimate the cost or timing of completing development programs or when product-related cash inflows might begin. Risks include clinical and regulatory uncertainty, dependence on third-party research organizations and manufacturers, limited resources, the need for additional capital, and the possibility of Nasdaq delisting. Vendor agreements had an estimated $3.87 million of costs to complete at June 30 and generally could be terminated with notice. A $1 million KRICT milestone is payable if a related product receives marketing approval; that milestone had not occurred. The filing also describes potential RX-0201 Asia royalties and licensing payments to Next BT, with no payments made as of quarter-end.
Key facts for investors to verify
- Confirm the filing identity: the supplied document is for Rexahn Pharmaceuticals, not Opus Genetics.
- Review the underlying RX-3117 trial data and the basis for the preliminary response-rate and progression-free-survival figures.
- Verify receipt of BioSense’s remaining $1.5 million upfront payment and the timing and conditions for recognizing collaboration revenue.
- Assess the cash runway against ongoing burn, planned clinical spending, and the availability and potential dilution of future financing.
- Evaluate warrant-related noncash gains separately from operating performance, and review the potential dilution from outstanding warrants.
- Monitor Nasdaq listing compliance and the development decisions for RX-5902 and other programs.